
Control Ab
Chimeric Ab
AB-H1
AB-H3
AB-H6
AB-H11
AB-H22
AB-H24
AB-H26
AB-H63
AB-H64
AB-H71
% huCD33 of Control
120
100
80
60
40
20
0
0.0001
0.001
0.01
0.1
1
Ab conc (ug/mL)

FIG. 1


Control Ab
Chimeric Ab
AB-H64
AB-64.1
AB-64.2
AB-64.6
AB-64.7
% huCD33 of Control
120
100
80
60
40
20
0
0.0001
0.001
0.01
0.1
1
Ab conc (ug/mL)

FIG. 2


EC50 (nM)
huIgG1
AB-64.1 0.71
AB-64.1.2 0.55
AB-64.1.8 0.62
Relative Ligand Binding
120
100
80
60
40
20
0
0.01
0.1
1
Ab Conc (ug/mL)

FIG. 3


AB-64.1 G1
AB-64.1 G2
AB-64.1 G1 SELF
AB-64.1 G1 LALAPS
AB-64.1 G1 N297A
% hCD3 of Control
100
80
60
40
20
0
0.001
0.01
0.1
1
Ab Conc (ug/mL)

FIG. 4


control
AB-64.1 hulgG1
AB-64.1 hulgG2
AB-64.1 hulgG1 LALAPS
% remaining CD33
150
100
50
0
0
5
10
15
20
25
Days Post Dose

FIG. 5

FIG. 6A


150
100
50
0
% Remaining CD33
0
2
4
6
Days Post Dose
control
AB-64.1 hulgG1
AB-64.1 hulgG2
AB-64.1 hulgG1 LALAPS

FIG. 6B


120
100
80
60
40
20
0
% remaining CD33
control
AB-64.1 hulgG1
AB-64.1 hulgG2
AB-64.1 hulgG1 LALAPS
blood
spleen


U937
HL-60
6:1
10:1
25:1
Fold over control
p < 0.01
p < 0.05
control
AB-64.1 huIgG1
AB-64.1 huIgG2
AB-64.1 huIgG1 SELF
AB-64.1 huIgG1 LALAPS
280-31-01(mut)
media

FIG. 7


Fold over control
0
1
2
Control
AB-64.1 huIgG1
AB-64.1 huIgG2
AB-64.2 huIgG1 SELF
AB-64.1 huIgG1 LALAPS
AB-64.1 huIgG1 N297A
Media

FIG. 8

FIG. 9A


Microglia
% huCD33 of Control
125
100
75
50
25
0
Day 1
Day 3
Day 6
Day 10
Day 14
Day 20
Day 28
2 mg/kg
10 mg/kg
40 mg/kg

FIG. 9B


% huSiglec-7 of Control
125
100
75
50
25
0
Day 1
Day 3
Day 6
Day 10
Day 14
Day 20
Day 28
2 mg/kg
10 mg/kg
40 mg/kg

FIG. 9C


Neutrophils
% huCD33 of Control
125
100
75
50
25
0
Day 1
Day 3
Day 6
Day 10
Day 14
Day 20
Day 28
2 mg/kg
10 mg/kg
40 mg/kg

FIG. 9D


Monocytes
% huCD33 of Control
125
100
75
50
25
0
Day 1
Day 3
Day 6
Day 10
Day 14
Day 20
Day 28
2 mg/kg
10 mg/kg
40 mg/kg